Emisphere Technologies, Inc. Announces 2007 Second Quarter Financi...(boration with Novartis Pharma AG -- C...),Health

-- Continuing the development of oral heparin; discussions with the US

Food and Drug Administration (FDA) has established a pathway for

registration to proceed into complete Phase III for the use of oral

heparin in the prevention of deep-vein thrombosis following elective

total hip replacement. Emisphere is in current discussions with

potential partners to complete the development of oral heparin in a

collaborative arrangement.

-- Continuing clinical development of oral insulin; an insulin/glucose

clamp study with a new formulation is being planned over a three-month

period starting early in the first quarter, which will provide further

data and information on the dosage. Collaborative partnerships will

then be investigated

Emisphere has five products in Phase I:

-- An Investigational New Drug application (IND) was filed by Genta

Incorporated on gallium nitrate on July 31, 2007

-- A program continues on an improved oral formulation of the antiviral

compound acyclovir with a pharmaceutical company outside of the United

States

-- A food-intake study for both GLP-1 and PYY will be undertaken later

this year at University Hospital, Switzerland

-- Parathyroid hormone continues on a progressive clinical development

path in collaboration with Novaris Pharma AG

Emisphere has 11 products in preclinical development:

-- Six projects with partners in obesity, osteoporosis, infectious

disease, diabetes, and CNS

-- Five projects without established collaborations for the therapies of

CNS, erectile dysfunction, cardiovascular disease, inflammation and

pain, and fertility treatment

-- Following completion of these pre-clinical projects, decisions would

then be taken to possibly proceed into future collaborations
'/>"/>

SOURCE Emisphere Technologies, Inc. Copyright©2007 PR Newswire.

0 GOOD